Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab + IP Chemotherapy +/- TACE in Metastatic Digestive System Neuroendocrine Cancer
NCT07712094Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Aug 2026
- Primary completion
- Feb 2029
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in neuroendocrine cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
neuroendocrine cancer
Beyond the preview
Go deeper on NCT07712094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07712094.